The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening

被引:129
作者
Salit, Irving E. [1 ,2 ]
Lytwyn, Alice [3 ,4 ]
Raboud, Janet [1 ,2 ]
Sano, Marie [1 ]
Chong, Sylvia [4 ]
Diong, Christina [1 ]
Chapman, William [5 ]
Mahony, James B. [4 ,6 ]
Tinmouth, Jill [1 ,2 ,7 ]
机构
[1] Univ Hlth Network, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Henderson Hosp, Hamilton, New Zealand
[4] McMaster Univ, Hamilton, ON L8S 4L8, Canada
[5] St Josephs Hosp, Toronto, ON, Canada
[6] St Josephs Healthcare, Hamilton, New Zealand
[7] Sunnybrook Med Ctr, Toronto, ON M4N 3M5, Canada
关键词
anal cancer; anoscopy; cancer screening; HIV; human papillomavirus; SQUAMOUS INTRAEPITHELIAL LESIONS; ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS; CERVICAL-CANCER; CELL CARCINOMA; POSITIVE MEN; NEOPLASIA; RISK; AIDS; ANUS;
D O I
10.1097/QAD.0b013e328339e592
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To assess anal oncogenic human papillomavirus (HPV) and anal cytology as screening tests for detecting high-grade anal intraepithelial neoplasia (AIN 2+), as this is an immediate anal cancer precursor. Design: Cross-sectional study of 401 HIV-positive men who have sex with men (MSM). The endpoint was histologically confirmed AIN 2+ obtained by high-resolution anoscopy. Cytology and biopsy specimens were assigned random numbers and independently assessed by two pathologists. Methods: We did concomitant anal cytology, anal HPV testing and HRA with directed biopsies without knowing the results of each intervention. The main outcome measures were the sensitivity, specificity, negative predictive value and positive predictive value of anal cytology and oncogenic HPV for the detection of AIN 2+. Results: Cytology was abnormal in 67% of patients: high-grade squamous intraepithelial lesion, 12%; low-grade squamous intraepithelial lesion, 43% and atypical squamous cells of undetermined significance, 12%. Biopsies were abnormal in 68% of patients: AIN 2+, 25% and AIN 1, 43%. HPV was detected in 93% with multiple HPV types in 92% and oncogenic HPV types in 88%. Test performance characteristics for the detection of AIN 2+ using any abnormality on anal cytology were: sensitivity 84%, specificity 39%, negative predictive value 88% and positive predictive value 31%; using oncogenic HPV: sensitivity 100%, specificity 16%, negative predictive value 100% and positive predictive value 28%. Conclusion: Anal cytology and HPV detection have high sensitivity but low specificity for detecting AIN 2+. HIV-positive men who have sex with men have a high prevalence of AIN 2+ and require high-resolution anoscopy for optimal detection of high-grade anal dysplasia. (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
引用
收藏
页码:1307 / 1313
页数:7
相关论文
共 50 条
  • [21] Cervical Cancer Screening With Human Papillomavirus DNA and Cytology in Japan
    Sasaki, Yuri
    Iwanari, Osamu
    Arakawa, Ichiro
    Moriya, Takuya
    Mikami, Yoshiki
    Iihara, Kuniko
    Konno, Ryo
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (03) : 523 - 529
  • [22] Association of Human Papillomavirus Infection and Abnormal Anal Cytology among HIV-Infected MSM in Beijing, China
    Yang, Yu
    Li, Xiangwei
    Zhang, Zhihui
    Qian, Han-Zhu
    Ruan, Yuhua
    Zhou, Feng
    Gao, Cong
    Li, Mufei
    Jin, Qi
    Gao, Lei
    [J]. PLOS ONE, 2012, 7 (04): : e35983
  • [23] Acceptability of anal cancer screening tests for women living with HIV in the EVVA study
    Kaufman, E.
    de Castro, C.
    Williamson, T.
    Lessard, B.
    Munoz, M.
    Mayrand, M. H.
    Burchell, A. N.
    Klein, M. B.
    Charest, L.
    Auger, M.
    Marcus, V
    Coutlee, F.
    de Pokomandy, A.
    [J]. CURRENT ONCOLOGY, 2020, 27 (01) : 19 - 26
  • [24] Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing
    Schiffman, Mark
    [J]. CANCER CYTOPATHOLOGY, 2007, 111 (03) : 145 - 153
  • [25] Topical application of a dual PI3K/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer
    Rademacher, Brooks L.
    Matkowskyj, Kristina A.
    LaCount, Emily D.
    Carchman, Evie H.
    [J]. EUROPEAN JOURNAL OF CANCER PREVENTION, 2019, 28 (06) : 483 - 491
  • [26] Diagnosis of anal human papillomavirus infection: polymerase chain reaction or cytology?
    Indinnimeo, Marileda
    d'Ettorre, Gabriella
    Fiore, Annalisa
    Ceccarelli, Giancarlo
    Ciardi, Antonio
    Degener, Anna Marta
    Moschella, Cosima Maria
    Izzo, Luciano
    Izzo, Sara
    Antonelli, Guido
    D'Angeli, Ilaria
    Vullo, Vincenzo
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (04) : E232 - E235
  • [27] Modeling the Balance of Benefits and Harms of Cervical Cancer Screening with Cytology and Human Papillomavirus Testing
    Malagon, Talia
    Mayrand, Marie-Helene
    Ogilvie, Gina
    Gotlieb, Walter H.
    Blake, Jennifer
    Bouchard, Celine
    Franco, Eduardo L.
    Kulasingam, Shalini
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (07) : 1436 - 1446
  • [28] Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM
    Wentzensen, Nicolas
    Follansbee, Stephen
    Borgonovo, Sylvia
    Tokugawa, Diane
    Schwartz, Lauren
    Lorey, Thomas S.
    Sahasrabuddhe, Vikrant V.
    Lamere, Brandon
    Gage, Julia C.
    Fetterman, Barbara
    Darragh, Teresa M.
    Castle, Philip E.
    [J]. AIDS, 2012, 26 (17) : 2185 - 2192
  • [29] Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program
    Hortlund, Maria
    Muhr, Laila Sara Arroyo
    Lagheden, Camilla
    Hjerpe, Anders
    Dillner, Joakim
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (12) : 2083 - 2090
  • [30] Human papillomavirus and anal cancer : Diagnosis, screening and therapy
    Dindo D.
    Riesterer O.
    Weber A.
    Hahnloser D.
    [J]. Der Gastroenterologe, 2010, 5 (4): : 318 - 325